Children in Bangladesh benefiting from the introduction of dual vaccines, Rachel Silverman, a political analyst at the Center for Global Development Think-Tank in the United States, said the most promising vaccines “are largely covered by advanced sales contracts, mainly from rich countries.” The Covax plan will address the growing threat of “vaccine nationalism” and prioritize vulnerable health systems, and CEPI front-line staff will lead the research and development of COVAX vaccines, which aims to develop three safe and effective vaccines that can be made available to countries participating in the COVAX facility. Nine vaccines are currently supported by CEPI; Seven of them are currently in clinical trials. Governments, vaccine manufacturers (in addition to their own research and development activities), organizations and individuals have so far allocated $1.4 billion for vaccine research and development, but an additional $1 billion is urgently needed to advance the portfolio. The vaccine of both companies goes through the first phases of testing. It aims to deter national governments from storing Covid 19 vaccines and to focus on vaccinating high-risk people in each country. Dr Richard Hatchett, CEO of Cepi, said: “This is an important milestone in the history of public health where the international community is coming together to fight this pandemic.” This is the production of vaccines for the global South by the World South, which helps us ensure that no country is left behind when it comes to accessing a COVID-19 vaccine,” said Dr. Seth Berkley, CEO of Gavi, vaccine Alliance. “The dynamism of our efforts to ensure global and equitable access to COVID-19 vaccines is increasing. Last week, we were able to announce the historic number of countries that are now part of the COVAX facility, and today we can announce more safe and effective doses of vaccines, especially for low- and middle-income countries. No country, rich or poor, should be queuing for COVID 19 vaccines; this collaboration brings us closer to that goal. He added that the scheme would guarantee vaccines for “some people in all countries and not for all people in some countries.” Based on two decades of experience in accelerating the availability of billions of dose vaccines, Gavi is launching an investment opportunity: the Gavi Advance Market Commitment for COVID-19 Vaccines (Gavi Covax AMC).
The full list of CEPI-supported vaccines is as follows: GAVI offers new support for cervical cancer and rubella vaccines Moderna vaccine also has fewer requirements for cold storage, which has been a problem for poor countries, especially in warmer areas, and for remote areas and limited electricity. The COVAX Facility, coordinated by Gavi, the Vaccine Alliance, is an important component of COVAX – the vaccine column of the AC Accelerator, a groundbreaking global collaboration involving vaccine manufacturers to accelerate the development, production and equal access to COVID 19 tests, treatments and vaccines. The overall objective of COVAX is to accelerate the development and production of COVID 19 vaccines and to ensure equitable and equitable access to all countries of the world. It will achieve this by sharing the risks associated with vaccine development and, if necessary, by investing in vaccine production in advance, so that vaccines can be used on a large scale as soon as they prove safe and effective, and by pooling purchases and purchasing power to obtain sufficient quantities to end the acute phase of the pandemic by 2021.